Get the latest tech news
China's Clinical Trial Boom
In 2017, there were just over 600 clinical trials initiated in China. By 2023, that number was nearly 2,000. How can American companies kick off a similar boom?
Amgen’s XGEVA, a medication used to treat bone cancer, was approved in 2019 without further testing requirements based on a global Phase 2 study that included no clinical trial sites in China. “China’s regulatory reforms have made it faster and cheaper to get drugs into humans, and the learning rate of the Chinese biopharma ecosystem seems a lot higher at the moment than the US or European ones.” Countries that adapt their frameworks to expedite start-up times, recognize credible foreign data, and balance the tradeoff between sufficient oversight and innovation-friendly policies stand to capture the next wave of drug discoveries.
Or read this on Hacker News
